HLA-B*07:02 | easYmer kit
Product Code:
IMM-1048-01
IMM-1048-01
Regulatory Status:
RUO
RUO
Shipping:
Dry Ice
Dry Ice
Storage:
-20 °C
-20 °C
No additional charges, what you see is what you pay! *
| Code | Size | Price |
|---|
| IMM-1048-01-050 | 50 Tests | £956.00 |
Quantity:
| IMM-1048-01-100 | 100 Tests | £1,220.00 |
Quantity:
| IMM-1048-01-150 | 150 Tests | £1,749.00 |
Quantity:
| IMM-1048-01-200 | 200 Tests | £2,278.00 |
Quantity:
| IMM-1048-01-250 | 250 Tests | £2,807.00 |
Quantity:
| IMM-1048-01-300 | 300 Tests | £3,336.00 |
Quantity:
| IMM-1048-01-500 | 500 Tests | £3,865.00 |
Quantity:
Prices exclude any Taxes / VAT
Stay in control of your spending. These prices have no additional charges to UK mainland customers, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: Denmark.
Typical lead time: 7-10 working days.
Contact us for more accurate information.
Typical lead time: 7-10 working days.
Contact us for more accurate information.
- Further Information
- References
- Show All
Further Information
Description:
HLA-Class I easYmer® is a highly active formulation of peptide-receptive HLA class I (HLA-I) molecules (no artificial Cys-bonds linking heavy chain and b2m). Add Peptides of interest to generate specific peptide-HLA class I monomers. The loading efficacy can be validated in a FACS-based bead assay. The monomers can easily be tetramerised with fluorophore-conjugated streptavidin and used to stain cognate T cells for analysis in a flow cytometric assay. The easYmer® technology seamlessly enables: Large-scale production of pMHC monomers with a single epitope for screening a large number of samples, parallel production and screening of pMHC monomers with many different peptide epitope candidates and screening and validation of peptide-HLA-I binding. easYmers® are available in aliquots of 50 Tests (corresponding to 20 ug of pMHC)
References
- Acevedo, GR; et.al.; In Silico Guided Discovery of Novel Class I and II Trypanosoma cruzi Epitopes Recognized by T Cells from Chagas' Disease Patients; Journal of immunology (Baltimore, Md. : 1950); 2020; 204(6):1571-1581PubMed ID:32060134; DOI: 10.4049/jimmunol.1900873; https://journals.aai.org/jimmunol/article/204/6/1571/107771
- Schulien, I; et.al.; Characterization of pre-existing and induced SARS-CoV-2-specific CD8+ T cells; Nature medicine; 2021; 27(1):78-85PubMed ID:33184509; DOI: 10.1038/s41591-020-01143-2; https://www.nature.com/articles/s41591-020-01143-2
- Schulien, I; et.al.; Ex vivo detection of SARS-CoV-2-specific CD8+ T cells: rapid induction, prolonged contraction, and formation of functional memory; bioRxiv; 2020; ():PubMed ID:; DOI: 10.1101/2020.08.13.249433; https://www.biorxiv.org/content/10.1101/2020.08.13.249433.abstract
- Hamza, H;Ghosh, M;L?ffler, MW;Rammensee, HG;Planz, O;; Identification and relative abundance of naturally presented and cross-reactive influenza A virus MHC class I-restricted T cell epitopes; Emerging microbes & infections; 2024; 13(1):2306959PubMed ID:38240239; DOI: 10.1080/22221751.2024.2306959; https://www.tandfonline.com/doi/abs/10.1080/22221751.2024.2306959
- Cieri, N; et.al.; Systematic identification of minor histocompatibility antigens predicts outcomes of allogeneic hematopoietic cell transplantation; Nature biotechnology; 2024; ():PubMed ID:39169264; DOI: 10.1038/s41587-024-02348-3; https://www.nature.com/articles/s41587-024-02348-3
- Shoumariyeh, K; et.al.; Impaired SARS-CoV-2-Specific CD8+ T Cells After Infection or Vaccination but Robust Hybrid T Cell Immunity in Patients with Multiple Myeloma; Vaccines; 2024; 12(11):PubMed ID:39591152; DOI: 10.3390/vaccines12111249; http://dx.doi.org/10.3390/vaccines12111249